Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Diagnostic Pathology
Published in: Diagnostic Pathology 1/2015

Open Access 01-12-2015 | Research

Loss of heterozygosity at D8S262: an early genetic event of hepatocarcinogenesis

Authors: Qiao Zhu, Li Gong, Xiaoyan Liu, Jun Wang, Pin Ren, Wendong Zhang, Li Yao, Xiujuan Han, Shaojun Zhu, Miao Lan, Yanhong Li, Wei Zhang

Published in: Diagnostic Pathology | Issue 1/2015

Login to get access

Abstract

Background

Hepatocellular carcinoma (HCC) is a multi-factor, multi-step, multi-gene and complicated process resulting from the accumulation of sequential genetic and epigenetic alterations. An important change among them is from precancerous lesions to HCC. However, only few studies have been reported about the sequential genetic changes during hepatocarcinogenesis.

Methods

We observed firstly molecular karyotypes of 10 matched HCC using Affymetrix single-nucleotide polymorphism (SNP) 6.0 arrays, and found chromosomal fragments with high incidence (more than 70 %) of loss of heterozygosity (LOH). Then, we selected 28 microsatellite markers at some gene spanning these chromosomal fragments, and examined the frequency of LOH of 128 matched HCC and 43 matched precancerous lesions-dysplastic nodules (DN) by a PCR-based analysis. Finally, we investigated the expression of proteins encoded by these genes in HCC, DN and the surrounding hepatic tissues.

Results

The result of Affymetrix SNP6.0 arrays demonstrated that more than 70 % (7/10) cases had chromosomal fragment deletion on 4q13.3-35.1, 8p23.2-21.2, 16q11.2-24.3, and 17p13.3-12. Among 28 microsatellite markers selected, LOH frequencies at D8S262 for DN and HCC were found to be the highest, 51.2 % and 72.7 %, respectively. Immunohistochemically, the positive rate of its adjacent gene CSMD1 in HCC, DN, and the surrounding hepatic tissues were 27.3 % (35/128), 75 % (33/44), and 82 % (105/128), respectively.

Conclusions

LOH at D8S262 may be associated with an early genetic event of hepatocarcinogenesis, and a predictor for the monitor and prevention of HCC.

Virtual Slides

Appendix
Available only for authorised users
Literature
1.
Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, Omata M, et al. Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol. 2010;44(4):239–45.PubMedCrossRef
2.
Bannasch P, Jahn UR, Hacker HJ, Su Q, Hoffmann W, Pichlmayr R, et al. Focal hepatic glycogenosis: a putative preneoplastic lesion associated with neoplasia and cirrhosis in explanted human livers. Int J Oncol. 1997;10(2):261–8.PubMed
3.
Su Q, Bannasch P. Relevance of hepatic preneoplasia for human hepatocarcinogenesis. Toxicol Pathol. 2003;31(1):126–33.PubMedCrossRef
4.
Plentz RR, Park YN, Lechel A, Kim H, Nellessen F, Langkopf BH, et al. Telomere shortening and inactivation of cell cycle checkpoints characterize human hepatocarcinogenesis. Hepatology. 2007;45(4):968–76.PubMedCrossRef
5.
Fischer G, Hartmann H, Droese M, Schauer A, Bock KW. Histochemical and immunohistochemical detection of putative preneoplastic liver foci in woman after long-term use of oral contraceptives. Virchows Arch B Cell Pathol. 1986;50(4):321–37.CrossRef
6.
Hirota N, Hamazaki M, Williams GM. Resistance to iron accumulation and presence of hepatitis B surface antigen in preneoplastic and neoplastic lesions in human haemochromatotic livers. Hepatogastroenterology. 1982;29(2):49–51.PubMed
7.
Karhunen PJ, Penttila A. Preneoplastic lesions of human liver. Hepatogastroenterology. 1987;34(1):10–5.PubMed
8.
Deugnier YM, Charalambous P, Le Quilleuc D, Turlin B, Searle J, Brissot P, et al. Preneoplastic significance of hepatic ironfree foci in genetic haemochromatosis: a study of 185 patients. Hepatology. 1993;18(6):1363–9.PubMed
9.
Gong L, Li YH, Su Q, Chu X, Zhang W. Clonality of nodular lesions in liver cirrhosis and chromosomal abnormalities in monoclonal nodules of altered hepatocytes. Histopathology. 2010;56(5):589–99.PubMedCrossRef
10.
Gong L, Wei LX, Ren P, Zhang WD, Liu XY, Han XJ, et al. Dysplastic nodules with glypican-3 positive immunostaining: a risk for early hepatocellular carcinoma. PLoS One. 2014;9(1):e87120.PubMedCentralPubMedCrossRef
11.
Park YN. Update on precursor and early lesions of hepatocellular carcinomas. Arch Pathol Lab Med. 2011;135(6):704–15.PubMed
12.
Tuefferd M, De Bondt A, Van Den Wyngaert I, Talloen W, Verbeke T, et al. Genome-wide copy number alterations detection in fresh frozen and matched FFPE samples using SNP 6.0 arrays. Genes Chromosomes Cancer. 2008;47(11):957–64.PubMedCrossRef
13.
Gorringe KL, Ramakrishna M, Williams LH, Sridhar A, Boyle SE, et al. Are there any more ovarian tumor suppressor genes? A new perspective using ultra high-resolution copy number and loss of heterozygosity analysis. Genes Chromosomes Cancer. 2009;48(10):931–42.PubMedCrossRef
14.
Clifford RJ, Zhang J, Meerzaman DM, Lyu MS, Hu Y, et al. Genetic variations at loci involved in the immune response are risk factors for hepatocellular carcinoma. Hepatology. 2010;52(6):2034–43.PubMedCrossRef
15.
Ng IO, Guan XY, Poon RT, Fan ST, Lee JM. Determination of the molecular relationship between multiple tumour nodules in hepatocellular carcinoma differentiates multicentric origin from intrahepatic metastasis. J Pathol. 2003;199(3):345–53.PubMedCrossRef
16.
Maggioni M, Coggi G, Cassani B, Bianchi P, Romagnoli S, et al. Molecular changes in hepatocellular dysplastic nodules on microdissected liver biopsies. Hepatology. 2000;32(5):942–6.PubMedCrossRef
17.
Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. Cancer Cell. 2004;5(3):215–9.PubMedCrossRef
18.
Feitelson MA, Sun B, Satiroglu Tufan NL, Liu J, Pan J, et al. Genetic mechanisms of hepatocarcinogenesis. Oncogene. 2002;21(16):2593–604.PubMedCrossRef
19.
Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet. 2002;31(4):339–46.PubMedCrossRef
20.
Kahng YS, Lee YS, Kim BK, Park WS, Lee JY, Kang CS. Loss of heterozygosity of chromosome 8p and 11p in the dysplastic nodule and hepatocellular carcinoma. J Gastroenterol Hepatol. 2003;18(4):430–6.PubMedCrossRef
21.
Lu T, Hano H, Meng C, Nagatsuma K, Chiba S, Ikegami M. Frequent loss of heterozygosity in two distinct regions, 8p23.1 and 8p22, in hepatocellular carcinoma. World J Gastroenterol. 2007;13(7):1090–7.PubMedCentralPubMedCrossRef
22.
Lu T, Hano H. Identification of minimal regions of deletion at 8p23.1-22 associated with metastasis of hepatocellular carcinoma. Liver Int. 2007;27(6):782–90.PubMedCrossRef
23.
Kamal M, Shaaban AM, Zhang L, Zhang L, Walker C, et al. Loss of CSMD1 expression is associated with high tumour grade and poor survival in invasive ductal breast carcinoma. Breast Cancer Res Treat. 2010;121(3):555–63.PubMedCrossRef
24.
Toomes C, Jackson A, Maguire K, Wood J, Gollin S, et al. The presence of multiple regions of homozygous deletion at the CSMD1 locus in oral squamous cell carcinoma question the role of CSMD1 in head and neck carcinogenesis. Genes Chromosom Cancer. 2003;37(2):132–40.PubMedCrossRef
25.
Ma C, Quesnelle KM, Sparano A, Rao S, Park MS, et al. Characterization CSMD1 in a large set of primary lung, head and neck, breast and skin cancer tissues. Cancer Biol Ther. 2009;8(10):29–38.CrossRef
26.
Farrell C, Crimm H, Meeh P, Croshaw R, Barbar T, et al. Somatic mutations to CSMD1 in colorectal adenocarcinomas. Cancer Biol Ther. 2008;7(4):609–13.PubMedCrossRef
27.
Henshall SM, Afar DEH, Hiller J, Horvath LG, Quinn DI, et al. Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res. 2003;63(14):4196–203.PubMed
28.
Midorikawa Y, Yamamato S, Tsuji S, Kamimura N, Ishikawa S, et al. Allelic imbalances and homozygous deletion on 8p23.2 for stepwise progression of hepatocarcinogenesis. Hepatology. 2009;49(2):513–22.PubMedCrossRef
29.
Paris PL, Andaya A, Fridlyand J, Jain AN, Weinberg V, et al. Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum Mol Genet. 2004;13(13):1303–13.PubMedCrossRef
Metadata
Title
Loss of heterozygosity at D8S262: an early genetic event of hepatocarcinogenesis
Authors
Qiao Zhu
Li Gong
Xiaoyan Liu
Jun Wang
Pin Ren
Wendong Zhang
Li Yao
Xiujuan Han
Shaojun Zhu
Miao Lan
Yanhong Li
Wei Zhang
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2015
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/s13000-015-0308-y

Other articles of this Issue 1/2015

Diagnostic Pathology 1/2015 Go to the issue

Case Report

Exuberant squamous metaplasia of the gastric mucosa in a patient with gastric adenocarcinoma

Research

Combination of serum RASSF1A methylation and AFP is a promising non-invasive biomarker for HCC patient with chronic HBV infection

Case Report

Paraspinal extramedullary hematopoiesis in hereditary spherocytosis with a concurrent follicular lymphoma: case report and review of the literature

Case Report

Rapid recurrence and bilateral lungs, multiple bone metastasis of malignant solitary fibrous tumor of the right occipital lobe: report of a case and review

Case Report

Spontaneous regression of plasmablastic lymphoma in an elderly human immunodeficiency virus (HIV)-negative patient

Case Report

Crystalloid podocytopathy with focal segmental glomerulosclerosis in PCM: a case report